



Japanese Patent Office Allows NanoDisk Patent Claims

July 25, 2011

San Francisco, CA – Lypro Biosciences, Inc. (Lypro Bio), announced that the Japanese Patent Office has allowed patent claims covering composition of matter, process, and methods of use for its novel drug delivery nanotechnology, NanoDisk. These claims are documented as Japanese Patent Certificate Numbers 4777873 and 4786538 which provide exclusive rights in Japan through 2024. The allowance follows on previously issued patent claims in the United States, India and Australia. The patent prosecution was led by Gladys Monroy of Morrison Foerster.

NanoDisk are elegant, ternary complexes comprised of a scaffold which binds and stabilizes a lipid bilayer into which therapeutic compounds are incorporated. NanoDisk increases the solubility and bioavailability of the therapeutic yielding a more potent and efficacious therapy. Furthermore NanoDisk technology facilitates targeting of drugs to specific cell receptors. This proprietary technology can be brought to bear in a number of disease areas including infectious disease and oncology. Lypro Bio has exclusive rights to the patent technology.

“The patent is an important component of Lypro Bio’s global strategy for protecting its intellectual property and ensuring long-term, global, market exclusivity,” said Michelle S. Call, President and CEO of Lypro Biosciences. “Japan is an important market for drug development and therapies. This new patent will enhance partnering opportunities for all of our product development programs.”

About Lypro Biosciences

Lypro Biosciences, Inc. is preclinical stage therapeutic company, located in the San Francisco Bay Area and financed by angel investors including Life Science Angels. Lypro Bio’s proprietary nanotechnology drug delivery platform, NanoDisk, has applications across numerous disease indications. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancers such as mantle cell lymphoma.

Contacts:

Michelle S. Call
President and CEO
Lypro Biosciences, Inc.
info@lyprobio.com
www.lyprobio.com
